English, Article edition: Long-Term Effects of Second-Generation Cholinesterase Inhibitors on Clinical Outcomes and Costs of Alzheimer J. Jaime Caro; Denis Getsios

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/92948
Physical Description
  • article
Language
  • English

Edition details

Title
  • Long-Term Effects of Second-Generation Cholinesterase Inhibitors on Clinical Outcomes and Costs of Alzheimer
Author
  • J. Jaime Caro
  • Denis Getsios
Physical Description
  • article
Notes
  • Alzheimer Data on the effectiveness of these drugs from information beyond the short-term clinical trials (e.g. long-term clinical trials and non-trial data) are now emerging. In most cases, the results indicate that, at least for some patients, continued treatment with cholinesterase inhibitors is effective in slowing cognitive decline. Whether these results translate to clinically and economically relevant outcomes is less clear. The AD2000 trial in particular, a 1-year, placebo-controlled trial, seems to suggest that cognitive benefits, even if maintained over the mid-to-long term, may not adequately reflect overall deterioration in patients. Naturalistic studies, as well as analyses of administrative data, however, mostly suggest that these benefits are real and relevant. The cost effectiveness of treatment has been evaluated primarily through modeling. These studies have shown that the costs of treatment can be offset by savings in other areas as a result of slowed disease progression. When all medical costs are considered, relatively small delays in disease progression are required to offset treatment costs, but a large portion of these offsetting savings are a result of delayed institutionalization. To payors not responsible for institutional care costs, these predicted economic advantages are less relevant. While data are limited, some research indicates that reductions in other costs may be sufficiently large to fully offset the costs of treatment. Economic comparisons among active treatments have only been made in one study so far. Based on meta-analyses of trial data and a model estimating disease progression, that study concluded that galantamine provided the best health and economic projections. Head-to-head studies, however, are limited and provide conflicting results. While the treatment of patients with Alzheimer
  • Alzheimer's-disease, Cholinesterase-inhibitors, Cost-analysis, Cost-effectiveness, Donepezil, Galantamine, Pharmacoeconomics, Rivastigmine
  • RePEc:wkh:dmhout:v:11:y:2003:i:10:p:617-631
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment